Detalhe da pesquisa
1.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med
; 374(26): 2542-52, 2016 Jun 30.
Artigo
Inglês
| MEDLINE | ID: mdl-27093365
2.
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Nat Cancer
; 1(12): 1204-1217, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35121932
3.
Scientific Twitter: The flow of paleontological communication across a topic network.
PLoS One
; 14(7): e0219688, 2019.
Artigo
Inglês
| MEDLINE | ID: mdl-31361749
4.
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.
JAMA Oncol
; 5(9): 1332-1339, 2019 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31154457
5.
Tuberculosis following PD-1 blockade for cancer immunotherapy.
Sci Transl Med
; 11(475)2019 01 16.
Artigo
Inglês
| MEDLINE | ID: mdl-30651320
6.
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
J Clin Oncol
; 37(9): 693-702, 2019 03 20.
Artigo
Inglês
| MEDLINE | ID: mdl-30726175
7.
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
J Immunother Cancer
; 6(1): 131, 2018 11 27.
Artigo
Inglês
| MEDLINE | ID: mdl-30482247
8.
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.
J Immunother Cancer
; 6(1): 99, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30285852